Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema is a research paper published in New England Journal of Medicine (2022). On theSindex it has a DataRank of 3.0. It has been cited 86 times, with 82 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.670
From this paper's citation signal
Citation Network Contribution
2.3
From 53 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 82 citers.
National Eye Institute
Grant: UG1EY014231
National Institutes of Health
Grant: 5UG1EY014231-20
DRCR Network
FWCI
14.31
Citation Percentile
1.0%
Influential Citations
2
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals